The role of type I interferon in the treatment of COVID‐19

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

(2021) Lucas Walz et al.   BMC INFECTIOUS DISEASES

Adaptive immunity to SARS-CoV-2 and COVID-19

(2021) Alessandro Sette et al.   CELL

A narrative review of pharmacologic treatments for COVID ‐19: safety considerations and ototoxicity

(2021) Christine Little et al.   LARYNGOSCOPE

Efficacy and Safety of Pegylated Interferon alfa-2b in Moderate COVID-19: A phase II, randomized, controlled, open-label study

(2021) Anuja Pandit et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells

(2021) Antoine Rebendenne et al.   JOURNAL OF VIROLOGY

SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways

(2021) Lulu Han et al.   JOURNAL OF MEDICAL VIROLOGY

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial

(2021) Ilad Alavi Darazam et al.   Scientific Reports

The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19

(2021) Kristina Schönfelder et al.   CYTOKINE

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology

(2020) Simon J. Cleary et al.   BRITISH JOURNAL OF PHARMACOLOGY

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19

(2020) Annsea Park et al.   Cell Host & Microbe

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

(2020) Meijuan Zheng et al.   Cellular & Molecular Immunology

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

(2020) Wen Zhang et al.   CLINICAL IMMUNOLOGY

Immunology of COVID-19: current state of the science

(2020) Nicolas Vabret et al.   IMMUNITY

Type I IFN immunoprofiling in COVID-19 patients

(2020) Sophie Trouillet-Assant et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019

(2020) Yonghong Zhang et al.   JOURNAL OF INFECTIOUS DISEASES

Treatment options for COVID-19: The reality and challenges

(2020) Shio-Shin Jean et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study

(2020) Ping Xu et al.   MICROBES AND INFECTION

Structural basis of receptor recognition by SARS-CoV-2

(2020) Jian Shang et al.   NATURE

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions

(2020) Sabari Nath Neerukonda et al.   Pathogens

Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial

(2020) Effat Davoudi-Monfared et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral activities of type I interferons to SARS-CoV-2 infection

(2020) Emily Mantlo et al.   ANTIVIRAL RESEARCH

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

(2020) Nan Wang et al.   Cell Host & Microbe

SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70

(2020) He-wei Jiang et al.   Cellular & Molecular Immunology

COVID-19 pathophysiology: A review

(2020) Koichi Yuki et al.   CLINICAL IMMUNOLOGY

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

(2020) Eleonora Aricò et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Resolution of coronavirus disease 2019 (COVID-19)

(2020) Khaled Habas et al.   Expert Review of Anti-Infective Therapy

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

(2020) Runhong Zhou et al.   IMMUNITY

Inhibition of SARS-CoV-2 by type I and type III interferons

(2020) Ulrike Felgenhauer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection

(2020) Nicola Clementi et al.   JOURNAL OF INFECTIOUS DISEASES

SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences

(2020) Melika Lotfi et al.   JOURNAL OF MEDICAL VIROLOGY

Extrapulmonary manifestations of COVID-19

(2020) Aakriti Gupta et al.   NATURE MEDICINE

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

(2020) Jérôme Hadjadj et al.   SCIENCE

Can interferons stop COVID-19 before it takes hold?

(2020) Meredith Wadman   SCIENCE

Interplay between SARS-CoV-2 and the type I interferon response

(2020) Margarida Sa Ribero et al.   PLoS Pathogens

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

(2020) Yin-Qiu Huang et al.   Frontiers in Pharmacology

Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells

(2020) Mahmood Yaseen Hachim et al.   Frontiers in Immunology

Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China

(2020) Chaowei Li et al.   Aging-US

Immune response in SARS-CoV-2 infection: the role of interferons type I and type III

(2020) Caciane Portela Sousa et al.   Brazilian Journal of Infectious Diseases

Minor allele of Interferon-Induced Transmembrane Protein-3 (IFITM3) polymorphism (rs12252) is covered against SARS-CoV-2 infection and mortality: a worldwide epidemiological investigation

(2020) Abhijit Pati et al.   JOURNAL OF INFECTIOUS DISEASES

Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience

(2020) Ricardo Pereda et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID‐19 patients: Clinical and laboratory characteristics

(2020) Saeid Taghiloo et al.   JOURNAL OF MEDICAL VIROLOGY

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.

(2020) Kumari G. Lokugamage et al.   JOURNAL OF VIROLOGY

Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor

(2020) Olusegun O. Onabajo et al.   NATURE GENETICS

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

(2020) Qian Zhang et al.   SCIENCE

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

(2020) Jin-Yan Li et al.   VIRUS RESEARCH

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

(2020) Yoriyuki Konno et al.   Cell Reports

Cytokines and COVID-19: friends or foes?

(2020) Mohsen Rokni et al.   Human Vaccines & Immunotherapeutics

Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review

(2020) Kawthar Mohamed et al.   BIOORGANIC CHEMISTRY

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

(2020) Faryal Khamis et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Animal models for SARS‐CoV‐2 research: A comprehensive literature review

(2020) Kabita Pandey et al.   Transboundary and Emerging Diseases

Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities

(2020) Qiong Zhou et al.   Viruses-Basel

Dysregulated Interferon Response Underlying Severe COVID-19

(2020) LeAnn Lopez et al.   Viruses-Basel

Strong Correlation between the Case Fatality Rate of COVID-19 and the rs6598045 Single Nucleotide Polymorphism (SNP) of the Interferon-Induced Transmembrane Protein 3 (IFITM3) Gene at the Population-Level

(2020) Yong-Chan Kim et al.   Genes

Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients

(2020) Parvaneh Baghaei et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Nebulised interferon beta-1a for patients with COVID-19

(2020) Nathan Peiffer-Smadja et al.   Lancet Respiratory Medicine

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Phillip D Monk et al.   Lancet Respiratory Medicine

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

(2019) Rudragouda Channappanavar et al.   JOURNAL OF CLINICAL INVESTIGATION

ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity

(2019) Mart M. Lamers et al.   Frontiers in Immunology

Adverse events following Cannabis for medical use in Tuscany: an analysis of the Italian Phytovigilance database

(2019) Giada Crescioli et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Origin and evolution of pathogenic coronaviruses

(2018) Jie Cui et al.   NATURE REVIEWS MICROBIOLOGY

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

(2016) Rudragouda Channappanavar et al.   Cell Host & Microbe

Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses

(2016) Huib H. Rabouw et al.   PLoS Pathogens

Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection

(2015) Allison L. Totura et al.   mBio

Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2'-O-Methyltransferase Activity

(2014) V. D. Menachery et al.   JOURNAL OF VIROLOGY

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

(2013) Darryl Falzarano et al.   Scientific Reports

Direct Effects of Type I Interferons on Cells of the Immune System

(2011) S. Hervas-Stubbs et al.   CLINICAL CANCER RESEARCH

The Role of Nuclear Factor κB in the Interferon Response

(2011) Lawrence M. Pfeffer   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters

(2010) Keiji Kuba et al.   PHARMACOLOGY & THERAPEUTICS

Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells to Severe Acute Respiratory Syndrome-Associated Coronavirus Infection

(2010) Tomoki Yoshikawa et al.   PLoS One

Toll-Like Receptor 4 Deficiency Increases Disease and Mortality after Mouse Hepatitis Virus Type 1 Infection of Susceptible C3H Mice

(2009) A. Khanolkar et al.   JOURNAL OF VIROLOGY

Innate immune response to viral infection

(2008) Shohei Koyama et al.   CYTOKINE

MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV

(2008) Timothy Sheahan et al.   PLoS Pathogens